Glycolytic enzymes have also become targets for cancer therapy and the corresponding compounds include “hexokinase 2 (HK2) (2-deoxyglucose, 3-bromopyruvic acid, trastuzumab, and lonidamine), PKM2 (substituted N,N′-diarylsulfonamides, substituted thienol[3,2]pyrrole[3,2d]pyridazinone scaffold, TEPP-46, DASA-58, cisplatin, and docetaxel), and lactate dehydrogenase (LDHA) (gossypol, FX11, galloflavin, FK866, oxamate, and paclitaxel) (Yu and Li, 2017)”. The gene discussed is HK2; the disease is cancer.